Background: There are three methods for
renal replacement therapy for end stage
chronic kidney disease; dialysis,
continuous ambulatory peritoneal dialysis, and
renal transplantation which is the best because of the least morbidity rate, the best survival rates, the best quality of life, and the best improvement in
activities of daily living. In the field, flow cytometry serves a well-established role in pre- and post-transplant crossmatching, and if it is combined with
human leukocyte antigen (HLA) immunophenotyping based on
DNA, it will produce a more sensitive prediction of the chronic graft rejection compared to
complement-dependent cytotoxicity crossmatching and can eliminate irrelevant
antibody (IgM). This is the first experience using this method in our hospital. The survival rate at one, five and ten years has been shown to be 99%, 97% and 96%, respectively; therefore, we wanted to find out the five year follow up of the patient. Case presentation: We evaluated a 20-year-old female with a history of pediatric
renal transplantation five years previously due to
end stage renal disease caused by bilateral parenchymatous renal disease. She had a history of
hypertension since December 2014 and underwent
hemodialysis for three months. The
transplantation took place in March 2015. A kidney from her mother was transplanted to recipient using end-to-side anastomoses. After five years, the patient was routinely monitored at the urology clinic, with
creatinine serum results between 1.5 and 2 mg/dL,
urea and
electrolyte serum levels within normal limits and she could resume normal life. Conclusions: Survival five years after the procedure showed a beneficial outcome of the method used.